Vyant Bio (NASDAQ:VYNT) Downgraded by Zacks Investment Research to “Sell”

Vyant Bio (NASDAQ:VYNTGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “VYANT BIO INC. operates through wholly-owned subsidiaries, StemoniX and vivoPharm. StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. VYANT BIO INC., formerly known as Cancer Genetics Inc., is based in CHERRY HILL, N.J. “

Separately, HC Wainwright lowered their price target on shares of Vyant Bio from $5.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, March 8th.

NASDAQ:VYNT traded up $0.01 during midday trading on Tuesday, reaching $0.78. 190 shares of the stock traded hands, compared to its average volume of 376,277. The company has a fifty day moving average of $1.12 and a 200 day moving average of $1.43. Vyant Bio has a 12 month low of $0.75 and a 12 month high of $4.24. The company has a current ratio of 4.27, a quick ratio of 4.19 and a debt-to-equity ratio of 0.01.

Hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC raised its holdings in Vyant Bio by 6.9% in the 3rd quarter. Geode Capital Management LLC now owns 188,802 shares of the company’s stock worth $439,000 after purchasing an additional 12,122 shares in the last quarter. Renaissance Technologies LLC bought a new position in Vyant Bio in the 3rd quarter worth $254,000. Morgan Stanley raised its holdings in Vyant Bio by 14,258.1% in the 2nd quarter. Morgan Stanley now owns 38,049 shares of the company’s stock worth $142,000 after purchasing an additional 37,784 shares in the last quarter. Citadel Advisors LLC bought a new position in Vyant Bio in the 2nd quarter worth $97,000. Finally, Virtu Financial LLC bought a new position in Vyant Bio in the 4th quarter worth $64,000. Institutional investors and hedge funds own 8.71% of the company’s stock.

About Vyant Bio (Get Rating)

Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).

Read More

Get a free copy of the Zacks research report on Vyant Bio (VYNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.